Addex And Janssen End Partnership; Epilepsy Candidate ADX71149 Rights Returned To Addex

Addex Therapeutics, a clinical-stage biotech company developing small-molecule allosteric modulators for neurological conditions, has announced the official termination of its partnership with Janssen Pharmaceuticals (now operating as J&J Innovative Medicine). This follows the previous decision to halt the development of their investigational epilepsy treatment, ADX71149, also known as JNJ-40411813. 

“ADX71149 is a high-quality asset which has completed three Phase 2 studies, so we are excited to regain control of its development from our partner with its high-quality data package and significant material. We are evaluating a number of high-value therapeutic indications for the future development of the program as well as pursuing discussions with a number of potential partners for the program”, said Tim Dyer, CEO of Addex. 

As part of the termination, all development and commercialization rights to ADX71149 have been returned to Addex. This move marks the end of the collaboration between Addex and Janssen.